Revision as of 12:26, 22 October 2022

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main colorectal cancer page for current regimens.

5 regimens on this page 5 variants on this page

Metastatic disease, first-line

Fluorouracil & Methotrexate (MF)

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Wils et al. 2003	1992-1994	Phase 3 (C)	MF & PALA	Did not meet endpoints of RR/PFS/OS

Chemotherapy

References

Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. link to original article PubMed

Fluorouracil & Mitomycin

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Price et al. 2004	1996-1998	Phase 3 (C)	Fluorouracil & Mitomycin; chronomodulated	Did not meet endpoints of FFS/OS

Chemotherapy

References

Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. link to original article PubMed

Fluorouracil & Semustine

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Baker et al. 1976	1973-1974	Phase 3 (C)	5-FU	Superior ORR
Engstrom et al. 1982 (ECOG E4275)	NR	Phase 3 (E-switch-ic)	1. 5-FU, Semustine, Vincristine 2. 5-FU, Dacarbazine, Semustine 3. 5-FU, Dacarbazine, Semustine, Vincristine 4. 5-FU & Hydrea	Did not meet endpoints of RR/OS

Chemotherapy

References

Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. link to original article PubMed
ECOG E4275: Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. link to original article PubMed

FOLFOX chronotherapy

FOLFOX: FOLinic acid, Fluorouracil, OXaliplatin

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Lévi et al. 1997	1991-1993	Phase 3 (E-switch-ic)	FOLFOX; CI	Superior TTF

Note: This schedule is "chronomodulated"; see paper for details.

Chemotherapy

Folinic acid (Leucovorin) 300 mg/m² IV over 12 hours once per day on days 1 to 5, given second, with 5-FU
Fluorouracil (5-FU) 600 mg/m² IV over 12 hours once per day on days 1 to 5, given second, with leucovorin
Oxaliplatin (Eloxatin) 20 mg/m² IV over 12 hours once per day on days 1 to 5, given first

21-day cycles

References

Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. link to original article contains dosing details in manuscript PubMed

@@ Line 1: / Line 1: @@
 The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Colorectal_cancer|main colorectal cancer page]] for current regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 7: / Line 6: @@
 |}
 {{TOC limit|limit=3}}
 =Metastatic disease, first-line=
 ==Fluorouracil & Methotrexate (MF) {{#subobject:bcd024|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:909280|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 20: / Line 17: @@
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://www.ejcancer.com/article/S0959-8049(02)00662-7 Wils et al. 2003]
+|[https://doi.org/10.1016/s0959-8049(02)00662-7 Wils et al. 2003]
 |1992-1994
 |style="background-color:#1a9851"|Phase 3 (C)
 |[[#MF_.26_PALA_77|MF & PALA]]
-| style="background-color:#ffffbf" |Seems not superior
+| style="background-color:#ffffbf" |Did not meet endpoints of RR/PFS/OS
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Fluorouracil (5-FU)]]
 *[[Methotrexate (MTX)]]
+</div></div>
 ===References===
-# Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; [[Study_Groups#EORTC|EORTC]] Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. [https://www.ejcancer.com/article/S0959-8049(02)00662-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12565987 PubMed]
+# Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; [[Study_Groups#EORTC|EORTC]] Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. [https://doi.org/10.1016/s0959-8049(02)00662-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12565987 PubMed]
 ==Fluorouracil & Mitomycin {{#subobject:29baf5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:e41b97|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 48: / Line 45: @@
 |style="background-color:#1a9851"|Phase 3 (C)
 |[[#Fluorouracil_.26_Mitomycin|Fluorouracil & Mitomycin]]; chronomodulated
-| style="background-color:#ffffbf" |Seems not superior
+| style="background-color:#ffffbf" |Did not meet endpoints of FFS/OS
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Fluorouracil (5-FU)]]
 *[[Mitomycin (Mutamycin)]]
+</div></div>
 ===References===
 # Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. [https://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70094-9/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/15025796 PubMed]
 ==Fluorouracil & Semustine {{#subobject:ddfd74|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:4df123|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 78: / Line 75: @@
 |style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 |1. [[#Fluorouracil.2C_Semustine.2C_Vincristine_99|5-FU, Semustine, Vincristine]]<br>2. [[#Dacarbazine.2C_Fluorouracil.2C_Semustine_99|5-FU, Dacarbazine, Semustine]]<br> 3. [[#Dacarbazine.2C_Fluorouracil.2C_Semustine.2C_Vincristine_99|5-FU, Dacarbazine, Semustine, Vincristine]]<br> 4. [[#Fluorouracil_.26_Hydroxyurea_88|5-FU & Hydrea]]
-| style="background-color:#ffffbf" |Seems not superior
+| style="background-color:#ffffbf" |Did not meet endpoints of RR/OS
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Fluorouracil (5-FU)]]
 *[[Semustine (MeCCNU)]]
+</div></div>
 ===References===
 # Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. [https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S link to original article] [https://pubmed.ncbi.nlm.nih.gov/779949 PubMed]
 # '''ECOG E4275:''' Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. [https://doi.org/10.1002/1097-0142(19820415)49:8%3C1555::AID-CNCR2820490807%3E3.0.CO;2-C link to original article] [https://pubmed.ncbi.nlm.nih.gov/7039814 PubMed]
 ==FOLFOX chronotherapy {{#subobject:7239a0|Regimen=1}}==
 FOLFOX: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:0af678|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 107: / Line 104: @@
 |-
 |}
-''This schedule is "chronomodulated"; see paper for details.''
+''Note: This schedule is "chronomodulated"; see paper for details.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Folinic acid (Leucovorin)]] 300 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with 5-FU'''
 *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with leucovorin'''
 *[[Oxaliplatin (Eloxatin)]] 20 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given first'''
 '''21-day cycles'''
+</div></div>
 ===References===
 # Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. [https://doi.org/10.1016/S0140673697033588 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9291901 PubMed]
 [[Category:Colorectal cancer regimens]]
 [[Category:Historical regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Gastrointestinal cancers]]

Difference between revisions of "Colorectal cancer - historical"

Revision as of 12:26, 22 October 2022

Contents

Metastatic disease, first-line

Fluorouracil & Methotrexate (MF)

Regimen

Chemotherapy

References

Fluorouracil & Mitomycin

Regimen

Chemotherapy

References

Fluorouracil & Semustine

Regimen

Chemotherapy

References

FOLFOX chronotherapy

Regimen

Chemotherapy

References

Navigation menu

Search